Immunotherapy in Eyelid Viral Papilloma

Launched by ZAGAZIG UNIVERSITY · Dec 5, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment for eyelid viral warts, also known as papillomas, using a method called immunotherapy. Instead of traditional surgical options that may be more damaging to the surrounding skin, this study is testing an injection of Candida antigens directly into the warts. The hope is that this approach will be less invasive and help patients recover more comfortably.

To participate in this trial, candidates must be at least 12 years old and have visible eyelid warts, whether just one or several, without any ongoing treatments for the warts. It's important that participants do not have certain conditions, such as pregnancy, breastfeeding, or weakened immune systems, and they should not have had any treatment for warts in the month leading up to the study. Those who join can expect to receive the injection and will be monitored for how well it works and any side effects. This trial is currently active, meaning they are still collecting data, but they are not looking for new participants at this time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with cutaneous eyelid viral warts whether single or multiple, with no concurrent systemic or topical treatment for warts. Patients aged more than 12 years, with sensitivity test, showed induration less than or equal to five mm. and patients can understand and comply with the requirements of the trials.
• Exclusion Criteria:
• • pregnancy, breastfeeding, patients with immunodeficiency; like diabetics. In addition, patients with a history of hypersensitivity to any used component in this trial, asthma, or allergic skin diseases. Moreover, patients on any treatment modality for warts at least 1 month before the start of the study.